|1.||Darnell, Robert B: 4 articles (07/2011 - 11/2003)|
|2.||Musunuru, Kiran: 2 articles (07/2011 - 01/2004)|
|3.||Ruggiu, Matteo: 2 articles (10/2005 - 11/2003)|
|4.||Ule, Jernej: 2 articles (10/2005 - 11/2003)|
|5.||Jensen, K B: 2 articles (02/2000 - 02/2000)|
|6.||Darnell, R B: 2 articles (02/2000 - 02/2000)|
|7.||Gor-García-Fogeda, María Dolores: 1 article (01/2016)|
|8.||Alguacil-Diego, Isabel M: 1 article (01/2016)|
|9.||Carratalá Tejada, María: 1 article (01/2016)|
|10.||Molina-Rueda, Francisco: 1 article (01/2016)|
|1.||Parkinson Disease (Parkinson's Disease)
02/01/2012 - "The Parkinson's disease group significantly improved their results in TUG, STST, unipodal stance, 10-m walk test, CBM, POMA and force platform at the end of the 6-week training programme. "
01/01/2016 - "For those with Parkinson disease, the TGS showed sensitivity and the Tinetti Performance-Oriented Mobility Assessment (POMA) showed predictive capability for falls and mortality as well as intra- and interrater reliability. "
01/01/2014 - "The Unified Parkinson Disease Rating Scale (UPDRS) motor score, dynamic posturography, Berg Balance Scale, and Tinetti performance-oriented mobility assessment (POMA) were used as main outcome measures. "
01/01/2014 - "In this study, we investigated the usability of the performance-oriented mobility assessment (POMA) for predicting falls in stroke patients. "
03/01/2013 - "The purpose of this study was to determine the test-retest reliability and minimal detectable change (MDC) of the POMA and explore its cross-sectional and longitudinal construct validity for use in people early after stroke. "
04/01/2015 - "Clinical assessments, including the Postural Assessment Scale for Stroke Patients (PASS), balance subscale of the Performance Oriented Mobility Assessment (POMA-b), Fugl-Meyer Assessment, Barthel Index (BI), and Timed Up and Go test, were performed immediately before and after the intervention. "
01/01/2014 - "The POMA balance subscale is a valid tool for assessing the physical function and fall risk of stroke survivors. "
03/01/2013 - "Results support cross-sectional and longitudinal construct validity of the POMA in persons early after stroke and demonstrate validity and reliability to measure balance ability in this population.Video"
06/01/1995 - "The results obtained at two regional cancer centres in New Zealand using POMA compare favourably to those achieved in clinical trials performed at major international cancer centres."
03/01/2010 - "Colorectal adenocarcinoma, the most common tumor that metastasizes to the ovary, is often difficult to distinguish from primary ovarian mucinous adenocarcinoma (POMA). "
10/07/2005 - "Indicative of intriguing differences in the regulatory mechanisms for excitatory and inhibitory synaptic plasticity, LTP of sIPSC but not EPSC was abolished in mice lacking Nova-2, a neuronal-specific RNA binding protein that is an autoimmune target in paraneoplastic opsoclonus myoclonus ataxia (POMA) patients with latent cancer, reduced inhibitory control of movements, and dementia."
03/01/2005 - "Paraneoplastic opsoclonus myoclonus with ataxia (POMA) is more common in patients over 40 years of age and is usually associated with lung (especially small cell), breast and ovarian cancer but has also been reported with many other cancers. "
10/27/1998 - "Paraneoplastic opsoclonus myoclonus ataxia (POMA) is a neurologic disorder thought to be mediated by an autoimmune attack against onconeural disease antigens that are expressed by gynecologic or lung tumors and by neurons. "
|4.||Opsoclonus-Myoclonus Syndrome (Kinsbourne Syndrome)
01/01/2004 - "The Nova onconeural antigens are implicated in the pathogenesis of paraneoplastic opsoclonus-myoclonus-ataxia (POMA). "
07/13/2011 - "Nova onconeural antigens are neuron-specific RNA-binding proteins implicated in paraneoplastic opsoclonus-myoclonus-ataxia (POMA) syndrome. "
11/14/2003 - "Nova proteins are neuron-specific antigens targeted in paraneoplastic opsoclonus myoclonus ataxia (POMA), an autoimmune neurologic disease characterized by abnormal motor inhibition. "
11/15/2001 - "In patients suffering from paraneoplastic opsoclonus myoclonus ataxia (POMA), Nova-1 and Nova-2 proteins are present as auto-antigens. "
02/01/2000 - "We have combined genetic and biochemical approaches to analyze the function of the RNA-binding protein Nova-1, the paraneoplastic opsoclonus-myoclonus ataxia (POMA) antigen. "
03/01/2010 - "To refine our findings, large prospective studies on the predictive validity of the POMA in populations with mild, moderate and severe dementia are needed. "
03/01/2010 - "Application of the POMA in populations with moderate to severe dementia is hampered by feasibility problems. "
03/01/2010 - "We evaluated the clinimetric properties of the Tinetti Performance Oriented Mobility Assessment (POMA) in nursing home residents with dementia with a specific objective of predicting falls in the short term. "
03/01/2010 - "Is the Tinetti Performance Oriented Mobility Assessment (POMA) a feasible and valid predictor of short-term fall risk in nursing home residents with dementia?"
10/27/1998 - "The neuronal RNA-binding protein Nova-2 is implicated as the autoantigen targeted in POMA patients with dementia."
|2.||RNA-Binding Proteins (RNA-Binding Protein)
|3.||Proteins (Proteins, Gene)
|4.||Immune Sera (Antisera)
|7.||Vasoactive Intestinal Peptide (VIP (Vasoactive Intestinal Peptide))
|9.||RNA (Ribonucleic Acid)
|1.||Transplantation (Transplant Recipients)
|3.||Home Nursing (Nursing, Home)